- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05172609
An Exposure-Based Implementation Strategy to Decrease Clinician Anxiety Around Suicide Prevention
May 8, 2023 updated by: University of Pennsylvania
An Exposure-Based Implementation Strategy to Decrease Clinician Anxiety About Delivering Suicide Prevention Evidence-Based Practices
Study objectives are to design and pilot test a novel, exposure-based implementation strategy (EBIS) directly targeting clinician anxiety and low self-efficacy for use of evidence-based suicide screening, assessment, and intervention (SSAI) strategies with patients at risk for suicide in community settings.
Early phases of this study will develop the EBIS in partnership with community clinicians (n = 15).
The last phase of this study is a pilot clinical trial in which 40 community mental health clinicians will be randomized to receive either implementation as usual (IAU) or IAU+EBIS.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This exploratory project brings together an interdisciplinary team to design and pilot-test an exposure-based implementation strategy (EBIS) to target clinician-level anxiety about suicide screening, assessment, and intervention (SSAI) use.
We will test the effect of EBIS as an implementation strategy to augment Implementation as Usual (IAU) to enhance SSAI implementation in community mental health settings.
Specifically, this study first will use participatory design methods to develop and refine EBIS in collaboration with a stakeholder advisory board of clinicians, administrators, and content experts.
This study then will further iteratively refine EBIS with up to 15 clinicians in a pilot field test, using rapid cycle prototyping, in collaboration with the INSPIRE Methods Core.
Clinicians in Aim 2 will also provide qualitative feedback on EBIS' ability to mitigate anxiety and increase self-efficacy to deliver SSAIs to optimize our ability to engage target mechanisms of clinician anxiety.
In the final phase, this study will test the refined EBIS in a pilot implementation trial in which 40 community mental health clinicians will be randomized to receive either IAU or EBIS+IAU.
Primary clinical trial dependent variables are EBIS acceptability and feasibility, measured through questionnaires, interviews, and recruitment and retention statistics; this pilot trial is not intended to be powered to detect effects.
Secondary outcomes are preliminary effectiveness of EBIS on clinician-level implementation outcomes (SSAI adoption), and engagement of target implementation mechanisms (clinician anxiety and self-efficacy related to SSAI use), assessed via mixed methods.
Study Type
Interventional
Enrollment (Anticipated)
55
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emily M Becker-Haimes, PhD
- Phone Number: 215-573-5614
- Email: emily.haimes@pennmedicine.upenn.edu
Study Contact Backup
- Name: Megan Brady, B.A.
- Email: mhquire@pennmedicine.upenn.edu
Study Locations
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania Department of Psychiatry
-
Contact:
- Emily M Becker-Haimes, PhD
- Phone Number: 215-573-5614
- Email: emily.haimes@pennmedicine.upenn.edu
-
Contact:
- Megan Brady, BA
- Email: mhquire@pennmedicine.upenn.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Practicing mental health clinicians who provide direct mental health services to a treatment-seeking population
- Proficient in the English language
- Have access to a computer with internet connectivity
Exclusion Criteria:
- Participants will be excluded if they do not see any mental health patients that are at risk for suicide (e.g., they screen out high-risk patients for their individual practice).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Exposure Based Implementation Strategy (EBIS)
EBIS is informed by the latest science in exposure theory, borrowing heavily from brief exposure-based treatments that can be delivered in a single session.
We anticipate that EBIS will occur in four phases that map on to standard exposure therapy practice for patients with anxiety disorders: psychoeducation, assessment, practice, and relapse prevention; however, the final version will depend on the outcomes of the preparatory phases of this study.
Clinicians assigned to the EBIS arm will also receive all elements of IAU.
|
EBIS will include psychoeducation, assessment/hierarchy building.
guided practice, and guidance for application to clinical practice.
|
Active Comparator: Implementation as Usual (IAU)
Gold-standard IAU for SSAIs typically comprises pre-implementation preparation, didactic training, knowledge tests, experiential role plays, ongoing expert consultation, and providing certification status to clinicians who attain established benchmarks.
Pre-implementation preparation will include provision of materials.
Didactic training will occur in two parts: (1) suicide screening and assessment, and (2) Safety Planning Intervention (SPI) use.
Part one will consist of materials we previously developed based on community clinician feedback.
Part two will follow established SPI guidelines, including didactic training about SPI rationale and evidence base and experiential practice.
IAU also will include supports for electronic health record integration (e.g., previously developed templates).
After training, clinicians will receive 8 weeks of expert consultation to discuss implementation barriers and receive more role play practice.
|
IAU will consist of standard didactic training and ongoing consultation activities for enrolled clinicians
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician perception of EBIS acceptability for clinical practice
Time Frame: end of trial period (12 weeks)
|
Acceptability of EBIS will be measured via qualitative interviews with participants as well as the Acceptability of Intervention Measure (AIM), a 4-item, psychometrically-validated measure that indexes the extent to which stakeholders believe an implementation strategy is acceptable.
Items on the AIM are rated on a 5-point Likert scale (Range = 4-20) and higher scores indicate greater acceptability.
|
end of trial period (12 weeks)
|
Clinician perception of EBIS feasibility and utility for clinical practice
Time Frame: end of trial period (12 weeks)
|
Feasibility of EBIS will with the Feasibility of Intervention Measure (FIM), a 4-item measure that indexes the extent to which an implementation strategy is perceived as feasible.
Items on the FIM are rated on a 5-point Likert scale (Range = 4-20) and higher scores indicate greater acceptability.
|
end of trial period (12 weeks)
|
EBIS feasibility as assessed by clinician retention statistics
Time Frame: through study completion, an average of 12 weeks
|
Feasibility statistics for study retention (e.g., the proportion of recruited clinicians that agrees to be randomized to EBIS, he proportion of randomized clinicians that completes EBIS)
|
through study completion, an average of 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinician Anxiety
Time Frame: baseline, immediately post-intervention, two week follow up, and 12 week follow up
|
Clinician anxiety will be assessed via 10-point Subjective Units of Distress (SUDS), a 10-point Likert rating of subjective distress where 1 = Not at all Distressed and 10 = Very Distressed.
|
baseline, immediately post-intervention, two week follow up, and 12 week follow up
|
Clinician Self-Efficacy Questionnaire
Time Frame: baseline, immediately post-intervention, two week follow up, and 12 week follow up
|
Self-efficacy will be measured via responses to two statements on a 7-point scale measuring clinicians' self-efficacy to use SSAIs, using established question stems from behavioral science (e.g., "If I really wanted to, I could screen every patient I see for suicide risk").
Self-efficacy will be assessed separately for clinician self-efficacy for suicide screening and for use of the Safety Planning Intervention.
Higher scores indicate greater self-efficacy.
Scores will be averaged for analysis (Range = 1 - 7).
|
baseline, immediately post-intervention, two week follow up, and 12 week follow up
|
Screening use
Time Frame: baseline, immediately post-intervention, two week follow up, and 12 week follow up
|
Use of clinician routine suicide screening in all patient encounters will be indexed via chart-stimulated recall (CSR).
CSR is an established technique for examining clinician decision-making and clinical processes beyond what can be determined from chart review or self-report alone.
A research team member will review the clinician's deidentified caseload with them for the past clinic week.
For each patient seen that week, the researcher will ask brief questions related to the clinicians' suicide-related practices around screening for suicide risk.
|
baseline, immediately post-intervention, two week follow up, and 12 week follow up
|
Safety Planning Intervention Use
Time Frame: baseline, immediately post-intervention, two week follow up, and 12 week follow up
|
Clinician use of the Safety Planning Intervention when indicated (i.e., patient screens positive for suicide risk) will be indexed via chart-stimulated recall.
CSR is an established technique for examining clinician decision-making and clinical processes beyond what can be determined from chart review or self-report alone.
A research team member will review the clinician's caseload with them for the past clinic week.
For each patient seen that week for which the clinician reports screening for suicide risk, the researcher will ask brief questions (no more than 5 minutes) related to the clinicians' follow up intervention to assess clinician use of the Safety Planning Intervention.
|
baseline, immediately post-intervention, two week follow up, and 12 week follow up
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 29, 2023
Primary Completion (Anticipated)
February 28, 2025
Study Completion (Anticipated)
August 31, 2025
Study Registration Dates
First Submitted
August 25, 2021
First Submitted That Met QC Criteria
December 10, 2021
First Posted (Actual)
December 29, 2021
Study Record Updates
Last Update Posted (Actual)
May 10, 2023
Last Update Submitted That Met QC Criteria
May 8, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 356336
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Implementation Science
-
Duke UniversityActive, not recruitingImplementation Science | Medication Therapy ManagementUnited States
-
Washington University School of MedicineNational Heart, Lung, and Blood Institute (NHLBI)RecruitingImplementation Science | Behavior and Behavior MechanismsUnited States
-
University of Wisconsin, MadisonNational Institute on Aging (NIA)Not yet recruitingSurgery | Implementation Science | Geriatric Assessment | Health Services ResearchUnited States
-
Massachusetts General HospitalNot yet recruitingFood Insecurity | Behavioral Economics | Implementation Science | Dietary Quality
-
Erin RothwellEunice Kennedy Shriver National Institute of Child Health and Human Development...Not yet recruitingImplementation Science | Informed Consent | Neonatal Screening
-
Basque Health ServiceCarlos III Health Institute; European Union; Health Department of the Basque...Active, not recruitingImplementation Science | Inappropriate Prescribing | Behavioral SciencesSpain
-
Children's Hospital of PhiladelphiaNational Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationAntibiotic Stewardship | Implementation Science | Blood Culture RatesUnited States
-
Massachusetts General HospitalNot yet recruitingFood Insecurity | Diet, Healthy | Behavioral Economics | Implementation Science
-
Ottawa Hospital Research InstituteThe Hospital for Sick Children; Hopital Montfort; Unity Health Toronto; The Ottawa... and other collaboratorsEnrolling by invitationImplementation Science | Screening | Terminal Care | Palliative TherapyCanada
-
University of NebraskaNational Institute of General Medical Sciences (NIGMS)RecruitingEngagement, Patient | Implementation Science | Behavior, Health Risk | E Cigarette Use | Cessation, Smoking | Incentives | Peer Support | Media LiteracyUnited States
Clinical Trials on Exposure Based Implementation Strategy (EBIS)
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Heart...CompletedTuberculosis | Tuberculosis, PulmonaryUganda
-
VA Office of Research and DevelopmentUnknown
-
VA Office of Research and DevelopmentActive, not recruitingCognitive Function | Functional StatusUnited States
-
VA Office of Research and DevelopmentActive, not recruitingKnee OsteoarthritisUnited States
-
ZonMw: The Netherlands Organisation for Health...HAN University of Applied SciencesUnknown
-
Karolinska InstitutetCompleted
-
Geisinger ClinicNational Heart, Lung, and Blood Institute (NHLBI)Enrolling by invitationFamilial HypercholesterolemiaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedCancer | Colorectal Cancer | Colon Cancer | Rectum CancerUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI)RecruitingColo-rectal CancerUnited States
-
VA Office of Research and DevelopmentActive, not recruitingEarly AmbulationUnited States